{"title":"强生杨森生物技术公司投资微生物组研究与第二基因组合作","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1956","DOIUrl":null,"url":null,"abstract":"In a first for the field, Johnson & Johnson’s Janssen Biotech has formed a strategic collaboration with start-up Second Genome to characterise therapeutic mechanisms in ulcerative colitis (UC) that are mediated by the microbiome, the bacterial ecosystem living in and on the human body. Janssen will provide R&D support to Second Genome, funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development. The big pharma company’s portfolio includes Remicade® (infliximab), which is used in the treatment of moderately to severely active UC.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"27 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I6.1956\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a first for the field, Johnson & Johnson’s Janssen Biotech has formed a strategic collaboration with start-up Second Genome to characterise therapeutic mechanisms in ulcerative colitis (UC) that are mediated by the microbiome, the bacterial ecosystem living in and on the human body. Janssen will provide R&D support to Second Genome, funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development. The big pharma company’s portfolio includes Remicade® (infliximab), which is used in the treatment of moderately to severely active UC.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"27 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I6.1956\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I6.1956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration
In a first for the field, Johnson & Johnson’s Janssen Biotech has formed a strategic collaboration with start-up Second Genome to characterise therapeutic mechanisms in ulcerative colitis (UC) that are mediated by the microbiome, the bacterial ecosystem living in and on the human body. Janssen will provide R&D support to Second Genome, funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development. The big pharma company’s portfolio includes Remicade® (infliximab), which is used in the treatment of moderately to severely active UC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
